Bristol-Myers
Squibb Company BMY is pleased to announce that today the National
Institute of Health and Clinical Excellence (NICE) has
decided to recommend YERVOY® (ipilimumab), which is
approved in the European Union for the treatment of previously-treated
metastatic (advanced) melanoma, within the Final Appraisal Determination
(FAD). This important decision will enable eligible patients in England
and Wales to routinely access treatment with YERVOY through the National
Health Services (NHS).
“Today's decision is very welcome news and marks a major milestone in
the treatment of advanced melanoma,” said Dr. Paul Lorigan, Senior
Lecturer in Medical Oncology, the Christie NHS Foundation Trust.
“Ipilimumab's potential to provide a long-term survival benefit
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in